REDWOOD CITY, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference in Boston on Tuesday, August 11, 2026, at 1:00 PM PT / 4:00 PM ET.
A live and archived webcast of the fireside chat will be available on “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.
About Pulmonx Corporation Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD).?Pulmonx’s?Zephyr® Endobronchial Valve,?Chartis® Pulmonary Assessment System, LungTraX®?Platform, and?StratX® Lung Analyis Reports are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received U.S. Food and Drug Administration (FDA) Premarket Approval (PMA) to commercialize the Zephyr® Endobronchial Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option?for improving breathing,?activity?and quality of life in patients with severe emphysema. For more information on?the Zephyr?Valves and the company, please visit?www.Pulmonx.com.?
? Pulmonx®,?AeriSeal®,?Chartis®, LungTraX®,?StratX®, and Zephyr® are registered?trademarks of Pulmonx Corporation.?
